Inflammation is a critical component of tumor development and progression. Within the tumor environment, lymphocytes secrete cytokines and chemokines that promote tissue invasion, immune system evasion, migration, and metastasis of cancerous cells. Current therapies that target specific immune signals are only effective for a narrow set of patients and even then provide only a few months’ benefit, often with severely unpleasant side effects. Furthermore, because inflammatory responses can greatly diminish the therapeutic effect of chemotherapy, anti-inflammatory co-therapy is commonly prescribed, leading to an increased risk of GI bleeding or cardiovascular events. Balancing the relationship between the immune response and tumor biology is critical for both effective cancer treatment and disease management, including reducing cancer therapy-associated side effects.